sirolimus has been researched along with Abscess* in 2 studies
1 review(s) available for sirolimus and Abscess
Article | Year |
---|---|
[What's new in dermatological therapy?].
Several good-quality randomised trials brought useful information on how to manage severe skin infections and develop anti-staphylococcus strategies. Trials on common warts did not bring any valuable solution. Rituximab and omalizumab have seen their indications becoming more precise or broadened. Meta-analyses have been particularly numerous, but most of the time with no decisive conclusion, since this methodology presents strong limitations for studying safety data. Most important work has been rather directed toward analysing safety data rather than efficacy. Among the most important results, are those from a retrospective cohort of patients taking isotretinoin: suicidal risk has to be linked to severe acne itself, rather than to the drug. Topics: Abscess; Adalimumab; Anti-Bacterial Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cicatrix; Dermatologic Agents; Dermatology; Humans; Immunologic Factors; Immunosuppressive Agents; Isotretinoin; Methicillin-Resistant Staphylococcus aureus; Methotrexate; Omalizumab; Papillomavirus Vaccines; Rituximab; Sirolimus; Skin Diseases; Transforming Growth Factor beta3 | 2011 |
1 other study(ies) available for sirolimus and Abscess
Article | Year |
---|---|
Low viral load post-transplant lymphoproliferative disease localized within the tongue.
Post-transplant lymphoproliferative disease (PTLD) can occur in different sites, such as lymph nodes, allograft, and central nervous system. We report a 6-year-old girl with end-stage renal disease secondary to hypoplastic-dysplastic kidneys, who received a kidney transplant. Thirty months post transplant, she developed PTLD in the tongue, an area of muscular tissue only. At that time her peripheral blood Epstein-Barr viral (EBV) load was only 40 copies/10(5) lymphocytes, though the tumor was EB early RNA (EBER) positive. Immunosuppression was reduced with initial improvement in her symptoms. One month later, she returned with abdominal complaints and a contained cecal abscess. The excised cecal tissue revealed CD20 and EBER-positive lymphoid cells. At the same time, her peripheral blood EBV copy number rose to 400 copies/10(5) lymphocytes. She was successfully treated for the progressive PTLD by complete cessation of immunosuppression and a modified reduced-dose chemotherapy protocol plus rituximab. Partial immunosuppression was eventually re-introduced with sirolimus and prednisone. She remains in remission 60 months post transplant, and 30 months post PTLD, with serum creatinine value maintained at 1.3 mg/dL. Unusual localization of PTLD to areas in non-lymphoid tissue without regional lymphoid involvement may result in misleading low peripheral blood EBV viral loads. Topics: Abscess; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cecum; Child; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lymphoproliferative Disorders; Postoperative Complications; Prednisone; Rituximab; Sirolimus; Tongue Neoplasms; Viral Load | 2008 |